(Q29619682)

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19330875

30 April 2017

0 references

0 references

0 references

3

Thomas DL

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19330875

30 April 2017

author name string

Ghany MG

series ordinal

1

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19330875

30 April 2017

Strader DB

series ordinal

2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19330875

30 April 2017

Seeff LB

series ordinal

4

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19330875

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19330875

30 April 2017

language of work or name

1 reference

30 April 2017

publication date

April 2009

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19330875

30 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19330875

30 April 2017

volume

49

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19330875

30 April 2017

page(s)

1335-74

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19330875

30 April 2017

issue

4

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19330875

Global challenges in liver disease

30 April 2017

cites work

1 reference

The prevalence of hepatitis C virus infection in the United States, 1999 through 2002

21 January 2018

1 reference

Estimating the future health burden of chronic hepatitis C and human immunodeficiency virus infections in the United States

21 January 2018

1 reference

Testing for hepatitis C virus infection should be routine for persons at increased risk for infection

21 January 2018

1 reference

The risk of transfusion-transmitted viral infections. The Retrovirus Epidemiology Donor Study

21 January 2018

1 reference

Reconstruction of the hepatitis C virus epidemic in the US hemophilia population, 1940-1990.

21 January 2018

1 reference

Risk factors for perinatal transmission of hepatitis C virus (HCV) and the natural history of HCV infection acquired in infancy

21 January 2018

1 reference

Risk of hepatitis C seroconversion after occupational exposures in health care workers*1

21 January 2018

1 reference

Nosocomial transmission of HCV in the liver unit of a tertiary care center.

21 January 2018

1 reference

Prevalence and clinical course of chronic hepatitis C virus (HCV) infection and rate of HCV vertical transmission in a cohort of 15,250 pregnant women

21 January 2018

1 reference

Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection

21 January 2018

1 reference

Relationship of cosmetic procedures and drug use to hepatitis C and hepatitis B virus infections in a low-risk population

21 January 2018

1 reference

Shaving as potential source of hepatitis C virus infection

21 January 2018

1 reference

Epidemiology of hepatitis C in the East

21 January 2018

1 reference

Prevalence and risk factors for hepatitis C virus infection at an urban Veterans Administration medical center

21 January 2018

1 reference

A case-control study of risk factors for sporadic hepatitis C virus infection in the southwestern United States

21 January 2018

1 reference

Tattoos and body piercings in the United States: a national data set.

21 January 2018

1 reference

Tattoos and body piercings as indicators of adolescent risk-taking behaviors

21 January 2018

1 reference

Sensitivity and specificity of third-generation hepatitis C virus antibody detection assays: an analysis of the literature

21 January 2018

1 reference

Diagnostic discordance for hepatitis C virus infection in hemodialysis patients

21 January 2018

1 reference

Low-positive anti-hepatitis C virus enzyme immunoassay results: an important predictor of low likelihood of hepatitis C infection

21 January 2018

1 reference

What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories?

21 January 2018

1 reference

NAT of the United States and Canadian blood supply

21 January 2018

1 reference

Molecular diagnosis of viral hepatitis

21 January 2018

1 reference

Molecular diagnostics of hepatitis C virus infection: a systematic review

21 January 2018

1 reference

Standardization of hepatitis C virus RNA quantification

21 January 2018

1 reference

Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes

21 January 2018

1 reference

Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States

21 January 2018

1 reference

The liver biopsy in chronic hepatitis C: a view from the other side of the microscope

21 January 2018

1 reference

Classification of chronic viral hepatitis: a need for reassessment

21 January 2018

1 reference

An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group

21 January 2018

1 reference

Histological grading and staging of chronic hepatitis

21 January 2018

1 reference

Steatosis affects chronic hepatitis C progression in a genotype specific way

21 January 2018

1 reference

Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C.

21 January 2018

1 reference

Hepatic iron concentration as a predictor of response to interferon alfa therapy in chronic hepatitis C.

21 January 2018

1 reference

Impact of hepatic steatosis on viral kinetics and treatment outcome during antiviral treatment of chronic HCV infection

21 January 2018

1 reference

The impact of steatosis on disease progression and early and sustained treatment response in chronic hepatitis C patients

21 January 2018

1 reference

Do we still need a liver biopsy? Are the serum fibrosis tests ready for prime time?

21 January 2018

1 reference

Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF).

21 January 2018

1 reference

Noninvasive measures of liver fibrosis

21 January 2018

1 reference

Transient elastography: a new noninvasive method for assessment of hepatic fibrosis.

21 January 2018

1 reference

Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C.

21 January 2018

1 reference

Acute viral hepatitis increases liver stiffness values measured by transient elastography

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

21 January 2018

1 reference

Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection

21 January 2018

1 reference

Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose

21 January 2018

1 reference

Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome

21 January 2018

1 reference

Assessment of fibrosis progression in untreated irish women with chronic hepatitis C contracted from immunoglobulin anti-D.

21 January 2018

1 reference

Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis

21 January 2018

1 reference

Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA.

21 January 2018

1 reference

Chronic hepatitis C in patients with persistently normal alanine transaminase levels

21 January 2018

1 reference

Fibrosis progression in initially mild chronic hepatitis C.

21 January 2018

1 reference

Natural history of hepatitis C virus carriers with persistently normal aminotransferase levels.

21 January 2018

1 reference

A 24-week course of high-dose interferon-alpha plus ribavirin for Taiwanese chronic hepatitis C patients with persistently normal or near-normal alanine aminotransferase levels.

21 January 2018

1 reference

Interferon alfa-2b [correction of alpha-2b]and ribavirin for patients with chronic hepatitis C and normal ALT.

21 January 2018

1 reference

Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels

21 January 2018

1 reference

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

21 January 2018

1 reference

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

Low frequency of cirrhosis in a hepatitis C (genotype 1b) single-source outbreak in germany: a 20-year multicenter study

21 January 2018

1 reference

Outcome in a hepatitis C (genotype 1b) single source outbreak in Germany--a 25-year multicenter study

21 January 2018

1 reference

Prevalence and clinical outcome of hepatitis C infection in children who underwent cardiac surgery before the implementation of blood-donor screening

21 January 2018

1 reference

Clinical outcomes after transfusion-associated hepatitis C.

21 January 2018

1 reference

The long-term pathological evolution of chronic hepatitis C.

21 January 2018

1 reference

Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group

21 January 2018

1 reference

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

The relationship of acute transfusion-associated hepatitis to the development of cirrhosis in the presence of alcohol abuse

21 January 2018

1 reference

Steatosis: co-factor in other liver diseases.

21 January 2018

1 reference

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C.

21 January 2018

1 reference

National institutes of health consensus development conference statement: Management of hepatitis C: 2002 — June 10–12, 2002

21 January 2018

1 reference

Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.

21 January 2018

1 reference

Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy

21 January 2018

1 reference

Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C.

21 January 2018

1 reference

Hepatitis C virus RNA kinetics during the initial 12 weeks treatment with pegylated interferon-alpha 2a and ribavirin according to virological response

21 January 2018

1 reference

Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40 KD)/ribavirin.

21 January 2018

1 reference

Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial

21 January 2018

1 reference

Meta-analysis: a randomized trial of peginterferon plus ribavirin for the initial treatment of chronic hepatitis C genotype 4.

21 January 2018

1 reference

Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response.

21 January 2018

1 reference

Higher rate of sustained virologic response in chronic hepatitis C genotype 6 treated with 48 weeks versus 24 weeks of peginterferon plus ribavirin

21 January 2018

1 reference

Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients.

21 January 2018

1 reference

Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia

21 January 2018

1 reference

Treatment with pegylated interferon and ribavarin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study

21 January 2018

1 reference

Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.

21 January 2018

1 reference

Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C.

21 January 2018

1 reference

A randomised study of peginterferon and ribavirin for 16 versus 24 weeks in patients with genotype 2 chronic hepatitis C

21 January 2018

1 reference

Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin

21 January 2018

1 reference

High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.

21 January 2018

1 reference

Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin

21 January 2018

1 reference

Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis c genotype 1-infected slow responders.

21 January 2018

1 reference

Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.

21 January 2018

1 reference

Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study

21 January 2018

1 reference

Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy.

21 January 2018

1 reference

Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha

21 January 2018

1 reference

Cost-effectiveness of hematologic growth factors for anemia occurring during hepatitis C combination therapy

21 January 2018

1 reference

Venous thromboembolism and mortality associated with recombinant erythropoietin and darbepoetin administration for the treatment of cancer-associated anemia

21 January 2018

1 reference

Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C.

21 January 2018

1 reference

Neuropsychiatric adverse effects of interferon-alpha: recognition and management

21 January 2018

1 reference

The neuroimmunology of stress and depression.

21 January 2018

1 reference

Pretreatment symptoms and dosing regimen predict side-effects of interferon therapy for hepatitis C.

21 January 2018

1 reference

Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions.

21 January 2018

1 reference

Diagnosis and treatment of autoimmune hepatitis

21 January 2018

1 reference

A SELF-RATING DEPRESSION SCALE

21 January 2018

1 reference

An Inventory for Measuring Depression

21 January 2018

1 reference

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

The CES-D Scale: A Self-Report Depression Scale for Research in the General Population

21 January 2018

1 reference

Long-term follow-up of the hepatitis C HENCORE cohort: response to therapy and occurrence of liver-related complications

21 January 2018

1 reference

Sustained virological response to interferon-alpha is associated with improved outcome in HCV-related cirrhosis: a retrospective study

21 January 2018

1 reference

Sustained virologic response and clinical outcomes in patients with chronic hepatitis C and advanced fibrosis.

21 January 2018

1 reference

Management of hepatocellular carcinoma

21 January 2018

1 reference

Pegylated interferon and ribavirin failures: is retreatment an option?

21 January 2018

1 reference

Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study

21 January 2018

1 reference

Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders.

21 January 2018

1 reference

Prolonged Therapy of Advanced Chronic Hepatitis C with Low-Dose Peginterferon

21 January 2018

1 reference

Pegylated interferon alfa-2b plus ribavirin in the retreatment of interferon-ribavirin nonresponder patients

21 January 2018

1 reference

Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment

21 January 2018

1 reference

A randomized trial of pegylated interferon alpha-2b plus ribavirin in the retreatment of chronic hepatitis C.

21 January 2018

1 reference

Predictive value of ALT levels for histologic findings in chronic hepatitis C: a European collaborative study

21 January 2018

1 reference

Updated definitions of healthy ranges for serum alanine aminotransferase levels

21 January 2018

1 reference

Chronic hepatitis C with normal aminotransferase levels

21 January 2018

1 reference

Liver biopsy in the evaluation of patients with chronic hepatitis C who have repeatedly normal or near-normal serum alanine aminotransferase levels

21 January 2018

1 reference

Hepatitis C: the clinical spectrum of the disease

21 January 2018

1 reference

Hepatitis C virus carriers with persistently normal aminotransferase levels: healthy people or true patients?

21 January 2018

1 reference

Clinical management of HCV carriers with normal aminotransferase levels.

21 January 2018

1 reference

Clinical, histological, and virological features of hepatitis C virus carriers with persistently normal or abnormal alanine transaminase levels

21 January 2018

1 reference

Treatment of chronic hepatitis C patients with persistently normal alanine aminotransferase levels with the combination of peginterferon alpha-2a (40 kDa) plus ribavirin: impact on health-related quality of life

21 January 2018

1 reference

Sustained virological response rates and health-related quality of life after interferon and ribavirin therapy in patients with chronic hepatitis C virus infection and persistently normal alanine aminotransferase levels

21 January 2018

1 reference

The burden of hepatitis C virus infection in children: estimated direct medical costs over a 10-year period

21 January 2018

1 reference

Prevalence of hepatitis C virus infection in urban children

21 January 2018

1 reference

The Declining Risk of Post-Transfusion Hepatitis C Virus Infection

21 January 2018

1 reference

Increased detection of hepatitis C virus (HCV)-infected blood donors by a multiple-antigen HCV enzyme immunoassay

21 January 2018

1 reference

Changing epidemiologic pattern of chronic hepatitis C virus infection in Italian children

21 January 2018

1 reference

Hepatitis C and pregnancy

21 January 2018

1 reference

The management of HCV infected pregnant women and their children European paediatric HCV network

21 January 2018

1 reference

Prevalence of hepatitis C virus infection in asymptomatic anti-HIV1 negative pregnant women and their children

21 January 2018

1 reference

Infrequent vertical transmission of hepatitis C virus.

21 January 2018

1 reference

Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group

21 January 2018

1 reference

Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus

21 January 2018

1 reference

Role of breast-feeding in transmission of hepatitis C virus to infants of HCV-infected mothers

21 January 2018

1 reference

Absence of infection in breast-fed infants born to hepatitis C virus-infected mothers

21 January 2018

1 reference

Natural history of perinatal hepatitis C virus infection

21 January 2018

1 reference

Accuracy of HCV-RNA PCR tests for diagnosis or exclusion of vertically acquired HCV infection

21 January 2018

1 reference

Chronic hepatitis C in children: the pathological and clinical spectrum.

21 January 2018

1 reference

Spontaneous clearance of childhood hepatitis C virus infection

21 January 2018

1 reference

Hepatitis C virus infection acquired in childhood

21 January 2018

1 reference

Non-A, non-B hepatitis in children: a clinical, histologic, and serologic study.

21 January 2018

1 reference

Cryptogenic chronic liver disease and hepatitis C virus infection in children

21 January 2018

1 reference

Hepatitis C in children: a quaternary referral center perspective

21 January 2018

1 reference

Prevalence of Hepatitis C–Related Cirrhosis in Elderly Asian Patients Infected in Childhood

21 January 2018

1 reference

Chronic hepatitis C virus infection in childhood: clinical patterns and evolution in 224 white children.

21 January 2018

1 reference

Pathology of chronic hepatitis C in children: liver biopsy findings in the Peds-C Trial.

21 January 2018

1 reference

Clinical spectrum and histopathologic features of chronic hepatitis C infection in children

21 January 2018

1 reference

High dosage alpha-interferon for treatment of children and young adults with chronic hepatitis C disease

21 January 2018

1 reference

Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics

21 January 2018

1 reference

Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C.

21 January 2018

1 reference

Interferon-alpha and ribavirin treatment of hepatitis C in children with malignancy in remission.

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C.

21 January 2018

1 reference

Hepatitis C Virus prevalence among patients infected with Human Immunodeficiency Virus: a cross-sectional analysis of the US adult AIDS Clinical Trials Group

21 January 2018

1 reference

Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection

21 January 2018

1 reference

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

21 January 2018

1 reference

21 January 2018

1 reference

Hepatitis C virus (HCV) viremia in human immunodeficiency virus-seronegative and -seropositive patients with indeterminate HCV recombinant immunoblot assay

21 January 2018

1 reference

Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis

21 January 2018

1 reference

The HIV-coinfected patient: managing viral hepatitis

21 January 2018

1 reference

Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection

21 January 2018

1 reference

Hepatotoxicity of antiretroviral drugs is reduced after successful treatment of chronic hepatitis C in HIV-infected patients

21 January 2018

1 reference

Interferon alpha for the treatment of chronic hepatitis C in patients infected with human immunodeficiency virus. Hepatitis-HIV Spanish Study Group

21 January 2018

1 reference

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV co-infected patients.

21 January 2018

1 reference

Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons

21 January 2018

1 reference

Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients

21 January 2018

1 reference

Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial

21 January 2018

1 reference

Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy

21 January 2018

1 reference

Human immunodeficiency virus infection, anemia, and survival

21 January 2018

1 reference

Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons

21 January 2018

1 reference

Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection

21 January 2018

1 reference

Mitochondrial toxic effects and ribavirin

21 January 2018

1 reference

Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report

21 January 2018

1 reference

Lack of interference between ribavirin and nucleosidic analogues in HIV/HCV co-infected individuals undergoing concomitant antiretroviral and anti-HCV combination therapy

21 January 2018

1 reference

A survey of adverse events in 11,241 patients with chronic viral hepatitis treated with alfa interferon.

21 January 2018

1 reference

Interferon-alpha in patients with asymptomatic human immunodeficiency virus (HIV) infection. A randomized, placebo-controlled trial

21 January 2018

1 reference

Baseline CD4 Cell Count and Outcome of Pegylated Interferon Plus Ribavirin Therapy in HIV/Hepatitis C Virus-Coinfected Patients

21 January 2018

1 reference

Effect of baseline CD4 cell count on the efficacy and safety of peginterferon Alfa-2a (40KD) plus ribavirin in patients with HIV/hepatitis C virus coinfection

21 January 2018

1 reference

Responding to organ failure in HIV-infected patients

21 January 2018

1 reference

Survival and recurrence of hepatitis C after liver transplantation in patients coinfected with human immunodeficiency virus and hepatitis C virus

21 January 2018

1 reference

Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: the DOPPS.

21 January 2018

1 reference

Hepatitis C infection and the patient with end-stage renal disease

21 January 2018

1 reference

National surveillance of dialysis-associated diseases in the United States, 1997.

21 January 2018

1 reference

Hepatitis C and hemodialysis: a review

21 January 2018

1 reference

Chronic viral hepatitis in hemodialysis patients

21 January 2018

1 reference

A comprehensive study of the association between hepatitis C virus and glomerulopathy

21 January 2018

1 reference

Cryoglobulinemia related to hepatitis C virus infection

21 January 2018

1 reference

Multicenter study on hepatitis C virus-related cryoglobulinemic glomerulonephritis.

21 January 2018

1 reference

A role for hepatitis C virus infection in type II cryoglobulinemia

21 January 2018

1 reference

ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States

21 January 2018

1 reference

Cancer in patients on dialysis for end-stage renal disease: an international collaborative study

21 January 2018

1 reference

Long-term impact of hepatitis B, C virus infection on renal transplantation

21 January 2018

1 reference

Natural history of hepatitis B and C in renal allograft recipients

21 January 2018

1 reference

Association of hepatitis C with posttransplant diabetes in renal transplant patients on tacrolimus

21 January 2018

1 reference

Diabetes mellitus after kidney transplantation: a French multicentre observational study.

21 January 2018

1 reference

Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: meta-analysis of clinical studies

21 January 2018

1 reference

Recurrent glomerulonephritis following renal transplantation: an update

21 January 2018

1 reference

Recurrent glomerulonephritis after kidney transplantation.

21 January 2018

1 reference

Decreased serum aminotransferase activity in patients with chronic renal failure: impact on the detection of viral hepatitis

21 January 2018

1 reference

Is alanine aminotransferase a good marker of histologic hepatic damage in renal transplant patients with hepatitis C virus infection?

21 January 2018

1 reference

The effect of uremia on platelet contractile force, clot elastic modulus and bleeding time in hemodialysis patients

21 January 2018

1 reference

Platelet dysfunction and end-stage renal disease

21 January 2018

1 reference

Hepatitis C in chronic kidney disease: predialysis patients present more severe histological liver injury than hemodialysis patients?

21 January 2018

1 reference

Histopathological features of hepatitis C in renal transplant candidates [see comment]

21 January 2018

1 reference

Liver damage in hemodialysis patients with hepatitis C virus viremia: a prospective 10-year study

21 January 2018

1 reference

Hemodialysis clearance of intravenously administered ribavirin

21 January 2018

1 reference

Pegylated interferon-alpha2b: pharmacokinetics, pharmacodynamics, safety, and preliminary efficacy data. Hepatitis C Intervention Therapy Group

21 January 2018

1 reference

Single-dose pharmacokinetics and safety of pegylated interferon-alpha2b in patients with chronic renal dysfunction

21 January 2018

1 reference

Pegylated interferon and ribavirin treatment for hepatitis C in haemodialysis patients.

21 January 2018

1 reference

Interferon and ribavirin treatment in patients with hepatitis C-associated renal disease and renal insufficiency

21 January 2018

1 reference

Hepatitis C and renal disease: an update

21 January 2018

1 reference

Meta-analysis: interferon for the treatment of chronic hepatitis C in dialysis patients

21 January 2018

1 reference

Treatment of hepatitis C virus with interferon in hemodialysis patients awaiting kidney transplant

21 January 2018

1 reference

Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis

21 January 2018

1 reference

Treatment of HCV in patients with renal failure

21 January 2018

1 reference

Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot study

21 January 2018

1 reference

Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C.

21 January 2018

1 reference

Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection.

21 January 2018

1 reference

Pegylated-interferon alpha 2a treatment for chronic hepatitis C in patients on chronic haemodialysis.

21 January 2018

1 reference

Efficacy and tolerability of pegylated-interferon alpha-2a in hemodialysis patients with chronic hepatitis C.

21 January 2018

1 reference

The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kDa) plus ribavirin in haemodialysed patients awaiting renal transplant

21 January 2018

1 reference

Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.

21 January 2018

1 reference

Efficacy and tolerance of interferon-alpha(2b) in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment

21 January 2018

1 reference

Successful treatment of hepatitis C after kidney transplantation with combined interferon alpha-2b and ribavirin

21 January 2018

1 reference

Ultralow-dose alpha-interferon plus ribavirin for the treatment of active hepatitis C in renal transplant recipients.

21 January 2018

1 reference

Chronic hepatitis C virus infection in renal transplant: treatment and outcome

21 January 2018

1 reference

Histopathologic efficacy of ribavirin monotherapy in kidney allograft recipients with chronic hepatitis C.

21 January 2018

1 reference

Treatment of hepatitis C virus infection (HCV) after renal transplantation: implications for HCV-positive dialysis patients awaiting a kidney transplant

21 January 2018

1 reference

Hepatitis C virus-associated fibrosing cholestatic hepatitis after renal transplantation: response to interferon-alpha therapy

21 January 2018

1 reference

Treatment of hepatitis C-virus-related glomerulonephritis.

21 January 2018

1 reference

Interferon alfa-2a therapy in cryoglobulinemia associated with hepatitis C virus

21 January 2018

1 reference

Response to interferon alpha treatment and disappearance of cryoglobulinaemia in patients infected by hepatitis C virus

21 January 2018

1 reference

Interferon-alpha in combination with ribavirin as initial treatment for hepatitis C virus-associated cryoglobulinemic membranoproliferative glomerulonephritis

21 January 2018

1 reference

Hepatitis C virus-related cryoglobulinemic glomerulonephritis: long-term remission after antiviral therapy

21 January 2018

1 reference

Treatment with peg-interferon alfa-2b and ribavirin of hepatitis C virus-associated mixed cryoglobulinemia: a pilot study

21 January 2018

1 reference

PEGylated interferon alfa-2b and ribavirin treatment in patients with hepatitis C virus-related systemic vasculitis

21 January 2018

1 reference

Antiviral therapy for hepatitis C virus--associated mixed cryoglobulinemia vasculitis: a long-term followup study.

21 January 2018

1 reference

Hepatocellular carcinoma: recent trends in the United States

21 January 2018

1 reference

Peginterferon alfa-2b and ribavirin for the treatment of chronic hepatitis C in blacks and non-Hispanic whites

21 January 2018

1 reference

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1.

21 January 2018

1 reference

Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1.

21 January 2018

1 reference

Treatment of chronic hepatitis C virus in African Americans with genotypes 2 and 3.

21 January 2018

1 reference

Peginterferon alfa-2a (40 kd) and ribavirin for black American patients with chronic HCV genotype 1.

21 January 2018

1 reference

Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis

21 January 2018

1 reference

21 January 2018

1 reference

21 January 2018

1 reference

Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft

21 January 2018

1 reference

A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation

21 January 2018

1 reference

Antiviral therapy of patients with decompensated cirrhosis to prevent recurrence of hepatitis C after liver transplantation.

21 January 2018

1 reference

Infection with chronic hepatitis C virus and liver transplantation: a role for interferon therapy before transplantation.

21 January 2018

1 reference

Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy

21 January 2018

1 reference

Peginterferon alfa-2b and ribavirin in patients with hepatitis C virus and decompensated cirrhosis: a controlled study.

21 January 2018

1 reference

Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group

21 January 2018

1 reference

Five-year follow-up of hepatitis C-naïve heart transplant recipients who received hepatitis C-positive donor hearts

21 January 2018

1 reference

Hepatitis virus infections in heart transplant recipients: epidemiology, natural history, characteristics, and impact on survival

21 January 2018

1 reference

Hepatitis C-positive donors in heart transplantation.

21 January 2018

1 reference

Donor hepatitis-C seropositivity is an independent risk factor for the development of accelerated coronary vasculopathy and predicts outcome after cardiac transplantation

21 January 2018

1 reference

Outcomes after lung transplantation in patients with chronic hepatitis C virus infection

21 January 2018

1 reference

Treatment of hepatitis C in potential lung transplant candidates

21 January 2018

1 reference

A 10-year experience of liver transplantation for hepatitis C: analysis of factors determining outcome in over 500 patients

21 January 2018

1 reference

Long-term outcome of liver transplants for chronic hepatitis C: a 10-year follow-up

21 January 2018

1 reference

Fibrosis progression after liver transplantation in patients with recurrent hepatitis C.

21 January 2018

1 reference

A prospective evaluation of fibrosis progression in patients with recurrent hepatitis C virus following liver transplantation

21 January 2018

1 reference

The impact of disease recurrence on graft survival following liver transplantation: a single centre experience

21 January 2018

1 reference

Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials

21 January 2018

1 reference

Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment.

21 January 2018

1 reference

Preemptive therapy for hepatitis C virus after living-donor liver transplantation

21 January 2018

1 reference

A randomized study comparing ribavirin and interferon alfa monotherapy for hepatitis C recurrence after liver transplantation

21 January 2018

1 reference

Combination of interferon alfa-2b and ribavirin in liver transplant recipients with histological recurrent hepatitis C.

21 January 2018

1 reference

Interferon-alpha 2b plus ribavirin in patients with chronic hepatitis C after liver transplantation: a randomized study.

21 January 2018

1 reference

Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence

21 January 2018

1 reference

Efficacy, predictors of response, and potential risks associated with antiviral therapy in liver transplant recipients with recurrent hepatitis C.

21 January 2018

1 reference

Recurrent hepatitis C genotype 1b following liver transplantation: treatment with combination interferon-ribavirin therapy.

21 January 2018

1 reference

Interferon alpha 2b and ribavirin for the treatment of recurrent hepatitis C after liver transplantation: cohort study of 38 patients

21 January 2018

1 reference

Pegylated interferon alfa-2a and ribavirin for recurrent hepatitis C after liver transplantation

21 January 2018

1 reference

Treatment of recurrent hepatitis C after liver transplantation: a pilot study of peginterferon alfa-2b and ribavirin combination.

21 January 2018

1 reference

Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation

21 January 2018

1 reference

Treatment of patients with recurrent hepatitis C after liver transplantation with peginterferon alfa-2B plus ribavirin

21 January 2018

1 reference

Hepatitis C recurrence after liver transplantation: Viral and histologic response to full-dose PEG-interferon and ribavirin.

21 January 2018

1 reference

Sustained virologic response to therapy of recurrent hepatitis C after liver transplantation is related to early virologic response and dose adherence

21 January 2018

1 reference

Report of the monothematic EASL conference on liver transplantation for viral hepatitis (Paris, France, January 12-14, 2006).

21 January 2018

1 reference

A randomized study on Peg-interferon alfa-2a with or without ribavirin in liver transplant recipients with recurrent hepatitis C.

21 January 2018

1 reference

Efficacy of antiviral therapy on hepatitis C recurrence after liver transplantation: a randomized controlled study.

21 January 2018

1 reference

Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation.

21 January 2018

1 reference

Effects of interferon treatment on liver histology and allograft rejection in patients with recurrent hepatitis C following liver transplantation

21 January 2018

1 reference

Outcomes of acute rejection after interferon therapy in liver transplant recipients.

21 January 2018

1 reference

Pegylated interferon plus ribavirin for recurrent Hepatitis C infection after liver transplantation in naïve and non-responder patients on a stable immunosuppressive regimen.

21 January 2018

1 reference

Pegylated interferon and ribavirin for the recurrence of chronic hepatitis C genotype 1 in transplant patients

21 January 2018

1 reference

Natural history of clinically compensated hepatitis C virus-related graft cirrhosis after liver transplantation

21 January 2018

1 reference

Outcome after liver re-transplantation in patients with recurrent chronic hepatitis C.

21 January 2018

1 reference

Hepatitis C infection in patients undergoing liver retransplantation

21 January 2018

1 reference

High-dose interferon-alpha2b treatment prevents chronicity in acute hepatitis C: a pilot study

21 January 2018

1 reference

Treatment of acute hepatitis C with interferon alfa-2b

21 January 2018

1 reference

Acute hepatitis C: high rate of both spontaneous and treatment-induced viral clearance.

21 January 2018

1 reference

Short-term interferon-alfa therapy for acute hepatitis C: a randomized controlled trial

21 January 2018

1 reference

Dose-dependent and genotype-independent sustained virological response of a 12 week pegylated interferon alpha-2b treatment for acute hepatitis C.

21 January 2018

1 reference

A short course of pegylated interferon-alpha in acute HCV hepatitis

21 January 2018

1 reference

Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection

21 January 2018

1 reference

Prospective evaluation of community-acquired acute-phase hepatitis C virus infection

21 January 2018

1 reference

Is it justifiable to withhold treatment for hepatitis C from illicit-drug users?

21 January 2018

1 reference

Patterns of improvement after methadone treatment: 1 year follow-up results from the National Treatment Outcome Research Study.

21 January 2018

1 reference

Treating hepatitis C in methadone maintenance patients: an interim analysis

21 January 2018

1 reference

Adherence and mental side effects during hepatitis C treatment with interferon alfa and ribavirin in psychiatric risk groups

21 January 2018

1 reference

Protection against persistence of hepatitis C.

21 January 2018

1 reference

Lack of Protective Immunity Against Reinfection with Hepatitis C Virus

21 January 2018

1 reference

Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users

21 January 2018

1 reference

Screening for depressive symptoms among HCV-infected injection drug users: examination of the utility of the CES-D and the Beck Depression Inventory

21 January 2018

1 reference

Treatment of hepatitis C infection in injection drug users

21 January 2018

1 reference

Treatment for hepatitis C virus infection among current injection drug users in Australia

21 January 2018

1 reference

Hepatitis C disease among injection drug users: knowledge, perceived risk and willingness to receive treatment

21 January 2018

1 reference

The impact of barriers to hepatitis C virus treatment in recovering heroin users maintained on methadone

21 January 2018

1 reference

Psychiatric complications of long-term interferon alfa therapy.

21 January 2018

1 reference

Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.

21 January 2018

1 reference

Impact of alcohol on the histological and clinical progression of hepatitis C infection.

21 January 2018

1 reference

Independent and combined action of hepatitis C virus infection and alcohol consumption on the risk of symptomatic liver cirrhosis

21 January 2018

1 reference

Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study

21 January 2018

1 reference

Progression of type C chronic hepatitis to liver cirrhosis and hepatocellular carcinoma--its relationship to alcohol drinking and the age of transfusion.

21 January 2018

1 reference

Effect of alcohol consumption on serum hepatitis C virus RNA and histological lesions in chronic hepatitis C.

21 January 2018

1 reference

Intrahepatic hepatitis C virus replication is increased in patients with regular alcohol consumption

21 January 2018

1 reference

Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection

21 January 2018

1 reference

Contribution of obesity to hepatitis C-related fibrosis progression

21 January 2018

1 reference

Independent and additive effect modification of hepatitis C and B viruses infection on the development of chronic hepatitis

21 January 2018

1 reference

Complementary and alternative medicine in chronic liver disease

21 January 2018

1 reference

Use of complementary and alternative medicine in patients with liver disease

21 January 2018

1 reference

Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial.

21 January 2018

1 reference

Prevalence of hepatitis B and C viruses and human immunodeficiency virus infections in women of reproductive age.

21 January 2018

2 references

21 January 2018

12 December 2020

When and how to treat acute hepatitis C?

1 reference

Pharmacokinetics of alphaIFN-2b in chronic hepatitis C virus patients undergoing chronic hemodialysis or with normal renal function: clinical implications.

21 January 2018

1 reference

12 December 2020

The kidney is the main site of interferon degradation

1 reference

12 December 2020

Recombinant interferon-alfa therapy in children with chronic hepatitis C.

1 reference

12 December 2020

End-stage renal disease and hepatitis C infection: comparison of alanine aminotransferase levels and liver histology in patients with and without renal damage

1 reference

12 December 2020

Hepatitis C virus infection. American Academy of Pediatrics. Committee on Infectious Diseases

1 reference

12 December 2020

Recommendations for preventing transmission of infections among chronic hemodialysis patients

1 reference

12 December 2020

Peginterferon Alfa-2b Therapy in Acute Hepatitis C: Impact of Onset of Therapy on Sustained Virologic Response

1 reference

12 December 2020

The burden of hepatitis C in the United States

1 reference

12 December 2020

Hepatitis C status of heart transplant recipients

1 reference

12 December 2020

Human immunodeficiency virus infection as risk factor for mother-to-child hepatitis C virus transmission; persistence of anti-hepatitis C virus in children is associated with the mother's anti-hepatitis C virus immunoblotting pattern

1 reference

12 December 2020

Effects of drugs on 2',3'-dideoxy-2',3'-didehydrothymidine phosphorylation in vitro

1 reference

12 December 2020

Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy

1 reference

12 December 2020

The natural history of chronic hepatitis C infection.

1 reference

12 December 2020

The clinical pharmacology of ribavirin

1 reference

12 December 2020

Interferon therapy for chronic hepatitis C in hemodialysis patients: increased serum levels of interferon

1 reference

12 December 2020

1 reference

12 December 2020

Interferon-alpha for prophylaxis of recurrent viral hepatitis C in liver transplant recipients: a prospective, randomized, controlled trial

1 reference

12 December 2020

Interferon-alpha may exacerbate cryoblobulinemia-related ischemic manifestations: an adverse effect potentially related to its anti-angiogenic activity

1 reference

12 December 2020

Relapses of chronic hepatitis C in HIV-infected patients who responded to interferon therapy. Hepatitis/HIV Spanish Study Group

1 reference

12 December 2020

Fibrosis in chronic hepatitis C correlates significantly with body mass index and steatosis

1 reference

12 December 2020

Development of hepatocellular carcinoma in patients with chronic hepatitis C who had a sustained virological response to interferon therapy: a multicenter, retrospective cohort study of 1124 patients

1 reference

12 December 2020

Pharmacokinetics of peginterferons

1 reference

12 December 2020

Renal Filtration, Absorption and Catabolism of Human Alpha Interferon

1 reference

12 December 2020

Role of liver biopsy in the management of chronic liver disease: selective rather than routine

1 reference

12 December 2020

Guidelines for laboratory testing and result reporting of antibody to hepatitis C virus. Centers for Disease Control and Prevention.

1 reference

12 December 2020

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

1 reference

12 December 2020

Course and outcome of hepatitis C

1 reference

12 December 2020

Recurrent and acquired hepatitis C viral infection in liver transplant recipients

1 reference

12 December 2020

Analysis of safety and efficacy of pegylated-interferon alpha-2a in hepatitis C virus positive hemodialysis patients: results from a large, multicenter audit

1 reference

12 December 2020

Loss of antibodies against hepatitis C virus in HIV-seropositive intravenous drug users

1 reference

12 December 2020

Natural history of hepatitis C

1 reference

12 December 2020

Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus

1 reference

12 December 2020

Iron reduction before and during interferon therapy of chronic hepatitis C: results of a multicenter, randomized, controlled trial

1 reference

12 December 2020

Lack of mother-to-infant transmission of hepatitis C virus in human immunodeficiency virus-seronegative women: a prospective study with hepatitis C virus RNA testing

1 reference

12 December 2020

Diagnosis and monitoring of hepatic injury. I. Performance characteristics of laboratory tests

1 reference

12 December 2020

Randomized trial of pegylated interferon alpha-2b monotherapy in haemodialysis patients with chronic hepatitis C

1 reference

12 December 2020

Surveillance for acute viral hepatitis--United States, 2005

1 reference

12 December 2020

Screening for hepatitis C virus in human immunodeficiency virus-infected individuals

1 reference

12 December 2020

Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin.

1 reference

12 December 2020

Effects of mode of delivery and infant feeding on the risk of mother-to-child transmission of hepatitis C virus. European Paediatric Hepatitis C Virus Network

1 reference

12 December 2020

Fibrosis and disease progression in hepatitis C.

1 reference

12 December 2020

National Institutes of Health Consensus Development Conference: management of hepatitis C: 2002.

1 reference

12 December 2020

Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. Centers for Disease Control and Prevention

1 reference

12 December 2020

Impact of decreased serum transaminase levels on the evaluation of viral hepatitis in hemodialysis patients

1 reference

12 December 2020

Determination of hepatitis C virus genotype by direct sequence analysis of products generated with the Amplicor HCV test.

1 reference

12 December 2020

Effect of morphine, hydromorphone, methadone, mescaline, trypan blue, vitamin A, sodium salicylate, and caffeine on the serum interferon level in response to viral infection

1 reference

12 December 2020

Hepatitis and HIV infection during haemodialysis

1 reference

12 December 2020

Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation

1 reference

12 December 2020

Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety

1 reference

12 December 2020

Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients

1 reference

12 December 2020

Universal precautions prevent hepatitis C virus transmission: a 54 month follow-up of the Belgian Multicenter Study. The Universitaires Cliniques St-Luc (UCL) Collaborative Group

1 reference

12 December 2020

Transient elastography is unreliable for detection of cirrhosis in patients with acute liver damage

1 reference

12 December 2020

Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group

1 reference

12 December 2020

Chronic hepatitis. An update on terminology and reporting.

1 reference

12 December 2020

Uremic bleeding: pathogenesis and therapy

1 reference

12 December 2020

National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification

1 reference

12 December 2020

KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease.

1 reference

12 December 2020

Mother-to-infant transmission of hepatitis C virus

1 reference

12 December 2020

Children with hepatitis C.

1 reference

12 December 2020

Does the healthy hepatitis C virus carrier state really exist? An analysis using polymerase chain reaction

1 reference

12 December 2020

Hepatitis C transmission by cosmetic tattooing in women

1 reference

12 December 2020

Hepatitis C virus-related cryoglobulinemia and glomerulonephritis: pathogenesis and therapeutic strategies.

1 reference

12 December 2020

Herbal hepatotoxicity

1 reference

12 December 2020

Sexual activity as a risk factor for hepatitis C.

1 reference

12 December 2020

Response to interferon therapy in children with chronic hepatitis C

1 reference

12 December 2020

De novo membranoproliferative glomerulonephritis in hepatitis C virus-infected renal allograft recipients.

1 reference

12 December 2020

The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation

1 reference

12 December 2020

Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP)

1 reference

12 December 2020

Progressive renal failure and blindness due to retinal hemorrhage after interferon therapy for hepatitis C virus-associated membranoproliferative glomerulonephritis

1 reference

12 December 2020

Rituximab therapy for de novo mixed cryoglobulinemia in renal transplant patients

1 reference

12 December 2020

Prevention of spread of hepatitis C.

1 reference

12 December 2020

Are body piercing and tattooing safe fashions?

1 reference

12 December 2020

Persistent hepatitis C viraemia without liver disease

1 reference

12 December 2020

Hepatitis C viral infection is associated with fibrillary glomerulonephritis and immunotactoid glomerulopathy.

1 reference

12 December 2020

Standardized reporting of clinical practice guidelines: a proposal from the Conference on Guideline Standardization

1 reference

12 December 2020

Natural history of chronic hepatitis C

1 reference

12 December 2020

Fulminant Hepatitis Associated with Hepatitis A Virus Superinfection in Patients with Chronic Hepatitis C

1 reference

12 December 2020

Classification of chronic hepatitis: diagnosis, grading and staging

1 reference

12 December 2020

Sexually transmitted diseases treatment guidelines, 2006.

1 reference

12 December 2020

The role of liver biopsy in chronic hepatitis C.

1 reference

12 December 2020

Beauty treatments and risk of parenterally transmitted hepatitis: results from the hepatitis surveillance system in Italy

1 reference

12 December 2020

Renal involvement in hepatitis C infection: cryoglobulinemic glomerulonephritis

1 reference

12 December 2020

Efficacy and safety of peginterferon-alpha2b and ribavirin combination therapy in children with chronic hepatitis C infection

1 reference

12 December 2020

American Gastroenterological Association policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers

1 reference

12 December 2020

Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection

1 reference

7 January 2021

inferred from DOI database lookup

Plasma levels, safety, and 60-week efficacy of a once-daily double-boosted protease inhibitor regimen of atazanavir, saquinavir, and ritonavir

1 reference

7 January 2021

inferred from DOI database lookup

Peginterferon-α-2a (40KD) and Ribavirin for 16 or 24 Weeks in Patients With Genotype 2 or 3 Chronic Hepatitis C

1 reference

12 December 2020

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19330875

Identifiers

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017

363154

363154

1 reference

Consolidated OpenCitations Corpus – April 2017

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=19330875

0 references

2 references

30 April 2017

Consolidated OpenCitations Corpus – April 2017